Swahili
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
hypertrophy/kunona
Kiungo kimehifadhiwa kwenye clipboard
Ukurasa 1 kutoka 32 matokeo
Use of droloxifene for the treatment of protastic disease, endometriosis and obesity
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
FIELD OF THE INVENTION
This invention relates to remedies for prostate diseases, endometriosis and obesity comprising, as active ingredient, droloxifene having the chemical structure represented by the following formula, ##STR1## or a pharmaceutically acceptable salt thereof.
BACKGROUND OF THE
Bacteroides CECT 7771 and the use thereof in the prevention and treatment of excess weight, obesity and metabolic and immunological alterations
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
CROSS-REFERENCE TO RELATED APPLICATIONS
This U.S. patent application is a national stage application under 35 U.S.C. .sctn.371 of international application PCT/ES2013/070309, filed May 16, 2013, and claims the benefit of priority under 35 U.S.C. .sctn.119 of Spanish Patent Application No. 201230796,
Compounds and methods for modulation of estrogen receptors
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
Compounds and methods for modulation of estrogen receptors
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
Regulation of metabolism by miR-378
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
DESCRIPTION OF THE TEXT FILE SUBMITTED ELECTRONICALLY
The contents of the text file submitted electronically herewith are incorporated herein by reference in their entirety: A computer readable format copy of the Sequence Listing (filename: MIRG.sub.--022.sub.--01WO_SeqList_ST25.txt, date recorded:
Compounds and methods for modulation of estrogen receptors
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
Compounds and methods for modulation of estrogen receptors
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
Compounds and methods for modulation of estrogen receptors
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, including pharmaceutical compositions and uses thereof, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity.
BACKGROUND OF THE INVENTION
The estrogen
Compounds and methods for modulation of estrogen receptors
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, and to compounds for inhibiting cytokines, as well as to pharmaceutical compositions and methods related thereto.
BACKGROUND OF THE INVENTION
The estrogen hormone has a broad spectrum of effects on tissues in
Compounds and methods for modulation of estrogen receptors
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, and to compounds for inhibiting cytokines, as well as to pharmaceutical compositions and methods related thereto.
BACKGROUND OF THE INVENTION
The estrogen hormone has a broad spectrum of effects on tissues in
Method for regulating size of vascularized normal tissue
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
FIELD OF THE INVENTION
The present invention is directed generally to the field of treatment of obesity and other disorders characterized by proliferation of normal vascularized tissues, by the administration of effective amount of angiogenesis inhibitors.
BACKGROUND OF THE INVENTION
The prevalence
N-benzylindole modulators of PPARG
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
BACKGROUND
The peroxisome proliferator active receptors (PPARs), members of the nuclear hormone receptor superfamily, comprise several subtypes, such as PPAR.alpha., PPAR.beta., and PPAR.gamma.. The PPAR.gamma. subtype, also referred to as PPARG, is the target of the glitazone pharmaceutical agents
N-biphenylmethylindole modulators of PPARG
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
BACKGROUND
The peroxisome proliferator active receptors (PPARs), members of the nuclear hormone receptor superfamily, comprise several subtypes such as PPAR.alpha., PPAR.beta., and PPAR.gamma.. The PPAR.gamma. subtype, also referred to as PPARG, is the target of the glitazone pharmaceutical agents
Compounds and methods for modulation of estrogen receptors
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
TECHNICAL FIELD
This invention is generally directed to estrogen antagonists and agonists, and to compounds for inhibiting cytokines, and more specifically to compounds which selectively modulate estrogen receptor-beta (ER-.beta.) activity, as well as to pharmaceutical compositions and methods
Cardioprotective phosphonates and malonates
Watumiaji waliosajiliwa tu ndio wanaweza kutafsiri nakala
Ingia / Ingia
FIELD OF THE INVENTION
This invention relates to pyridoxine phosphonate analogues, to pyridoxine malonate analogues, to their preparation, to pharmaceutical compositions thereof, and to treatments for cardiovascular and related diseases, for example, hypertrophy, hypertension, congestive heart
Hifadhidata kamili ya mimea ya dawa inayoungwa mkono na sayansi
- Inafanya kazi katika lugha 55
- Uponyaji wa mitishamba unaungwa mkono na sayansi
- Kutambua mimea kwa picha
- Ramani ya GPS inayoshirikiana
- Soma machapisho ya kisayansi yanayohusiana na utafutaji wako
- Tafuta mimea ya dawa na athari zao
- Panga maslahi yako na fanya tarehe ya utafiti wa habari, majaribio ya kliniki na ruhusu
Andika dalili au ugonjwa na usome juu ya mimea ambayo inaweza kusaidia, chapa mimea na uone magonjwa na dalili ambazo hutumiwa dhidi yake.
* Habari zote zinategemea utafiti wa kisayansi uliochapishwa
